688658 悦康药业
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,446,087-35.30%4,196,3014,541,9454,965,7264,338,949
减:营业总成本2,682,131-24.73%3,960,3304,195,6124,317,4543,881,802
    其中:营业成本1,218,344-23.64%1,566,4201,605,7951,527,3551,474,602
               财务费用13,293167.28%(10,273)(32,680)(33,070)39,573
               资产减值损失(41,543)-58.68%(62,406)(52,034)(40,970)(21,681)
公允价值变动收益6,040157.60%(687)2,894----
投资收益3,461682.37%(321)1,0864,034--
    其中:对联营企业和合营企业的投资收益------------
营业利润(234,446)-247.39%231,753357,941636,823492,150
利润总额(237,052)-255.59%223,268349,526629,272495,137
减:所得税费用37,76421.38%35,77410,61985,54951,509
净利润(274,816)-326.66%187,494338,906543,723443,628
减:非控股权益(12,426)403.06%2,6983,721(1,593)1,491
股东净利润(262,390)-312.09%184,796335,185545,316442,137

市场价值指针
每股收益 (元) *-0.590-310.71%0.4100.7401.2101.230
每股派息 (元) *----0.2001.1000.6800.450
每股净资产 (元) *7.367-7.33%7.9738.8648.7197.958
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容